© 2024 Hawaiʻi Public Radio

Donate

Play Live Radio

Next Up:

0:00

0:00

0:00 0:00

Available On Air Stations

The Conversation

Limits of lecanemab, a new drug approved to treat Alzheimer's

Hawaiʻi Public Radio | By Catherine Cruz

Published January 11, 2023 at 4:35 PM HST

Plaques located in the gray matter of the brain are key indicators of Alzheimer's disease. — Dr. William Burke goes over a PET brain scan in 2018 at Banner Alzheimer's Institute in Phoenix.

Breakthrough, or not? On The Long View, we focused on the long road to finding the best way to treat Alzheimer's disease. Our Contributing editor Neal Milner joined us in-studio

Further reading:

Good overall look: "FDA approves Alzheimer’s drug lecanemab amid safety concerns"
A critic scientist’s experience: Essay by Rachael Neve
Silberner’s article: “The Reason There’s Been No Cure for Alzheimer’s”

This interview aired on The Conversation on Jan. 11, 2023. The Conversation airs weekdays at 11 a.m. on HPR-1.

Tags

The Conversation Neal Milner

Catherine Cruz

Catherine Cruz is the host of The Conversation. Originally from Guam, she spent more than 30 years at KITV, covering beats from government to education. Contact her at ccruz@hawaiipublicradio.org.

See stories by Catherine Cruz

Related Stories

The Conversation

Why is there a disconnect between public perception of the economy and the stats?

Catherine Cruz

Do you think our economy is struggling? You're not alone. For The Long View, contributing editor Neal Milner joined us to talk about why so many Americans think the economy is bad despite numbers indicating the contrary.
The Conversation

Is there really an increase in retail theft?

Catherine Cruz

Smash and grab cases have been in the headlines in Hawaiʻi and on the mainland. Contributing editor Neal Milner joined us to talk about the real crime stats.